The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
INTERVENTIONS FOR VALVULAR DISEASE AND HEART FAILURE
Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial
EuroIntervention 2016;12:e235-e243 published online e-edition June 2016. DOI: 10.4244/EIJV12I2A37
Alec Vahanian1*, MD; Marina Urena1, MD; Thomas Walther2, MD; Hendrik Treede3, MD; Olaf Wendler4, MD; Thierry Lefèvre5, MD; Mark S. Spence6, MD; Simon Redwood7, MD; Philipp Kahlert8, MD; Josep Rodes-Cabau9, MD; Jonathon Leipsic10, MD; John Webb10, MD
1. Bichat Claude Bernard Hospital-Paris VII University, Paris, France; 2. Kerckhoff Clinic, Bad Nauheim, Germany; 3. University Clinics Eppendorf, Hamburg, Germany; 4. King’s College Hospital, London, United Kingdom; 5. Institut Hospitalier Jacques Cartie
Aims: This study sought to investigate outcomes of transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 transcatheter heart valve (THV) in patients at intermediate risk for su